New ofloxacin to boost treatment compliance

Pascual Laboratories recently launched its own brand of ofloxacin, a widely tested and clinically proven antibacterial agent. 

This brand is marketed at 10 percent less than the originator brand in order to encourage treatment compliance among patients.

An enormous problem due to antibiotic-resistant has emerged over the years. This is mainly due to treatment non-compliance, a case where a patient does not complete the recommended course of antibiotic therapy. 

This poses a problem because incomplete antibiotic therapy will cause some bacteria to survive in the body. The surviving bacteria will develop resistance to some form of antibiotics.

When faced with this problem, the physician will have two choices – prescribe a higher dosage of the same antibiotic or switch to another antibiotic which has a broader spectrum and is more toxic. Either way, the patient is bound to spend more for his medicine.

There are a number of reasons that cause treatment non-compliance. Paramount among these reasons is the cost of the drug. Patients more often discontinue their medication because they cannot afford to sustain the treatment.

This economical pricing of the new ofloxacin will encourage full-dose compliance among patients, lessening the chances of antibiotic resistance and increasing the rate of successful therapeutic outcomes.

The introduction of a new ofloxacin is part of Pascual Laboratories’ commitment to relentlessly pursue quality, innovation and excellence for the service of Filipino patients. 

Ofloxacin is a prescription product. Patients are advised to seek a doctor’s prescription before using it.